Cargando…

Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans

OBJECTIVE: Glucocorticoids (GCs) are regarded as diabetogenic because they impair insulin sensitivity and islet-cell function. This study assessed whether treatment with the glucagon-like peptide receptor agonist (GLP-1 RA) exenatide (EXE) could prevent GC-induced glucose intolerance. RESEARCH DESIG...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Raalte, Daniël H., van Genugten, Renate E., Linssen, Margot M.L., Ouwens, D. Margriet, Diamant, Michaela
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024359/ https://www.ncbi.nlm.nih.gov/pubmed/21216851 http://dx.doi.org/10.2337/dc10-1677

Ejemplares similares

Glucose Intolerance and the Amount of Visceral Adipose Tissue Contribute to an Increase in Circulating Triglyceride Concentrations in Caucasian Obese Females
por: Berings, Margot, et al.
Publicado: (2012)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

Alpha1-antitrypsin ameliorates islet amyloid-induced glucose intolerance and β-cell dysfunction
por: Rodríguez-Comas, Júlia, et al.
Publicado: (2020)

Exenatide improves glucocorticoid-induced glucose intolerance in mice
por: Zhao, Ruiying, et al.
Publicado: (2011)

Intra-islet glucagon secretion and action in the regulation of glucose homeostasis
por: Wang, Qinghua, et al.
Publicado: (2013)

Transplantation of betacellulin-transduced islets improves glucose intolerance in diabetic mice
por: Song, Mi-Young, et al.
Publicado: (2014)

The crucial role of muscle glucocorticoid signaling in accelerating obesity and glucose intolerance via hyperinsulinemia
por: Yamazaki, Hiroki, et al.
Publicado: (2023)

Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
por: Yang, Shi-Bing, et al.
Publicado: (2011)

Differential Development of Glucose Intolerance and Pancreatic Islet Adaptation in Multiple Diet Induced Obesity Models
por: Omar, Bilal, et al.
Publicado: (2012)

The Global Transcriptional Response of Isolated Human Islets of Langerhans to Glucagon-Like Peptide-1 Receptor Agonist Liraglutide
por: Zhao, Xiaoning, et al.
Publicado: (2012)

Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans
por: Welch, Andrew A., et al.
Publicado: (2023)

Intestinal Ralstonia pickettii augments glucose intolerance in obesity
por: Udayappan, Shanthadevi D., et al.
Publicado: (2017)

NF-κB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action
por: Sheng, Liang, et al.
Publicado: (2012)

Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome
por: Fransson, Liselotte, et al.
Publicado: (2014)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE(–/–) Mice
por: Liu, Fuqiang, et al.
Publicado: (2020)

β-Cell dysfunction and insulin resistance in gestational glucose intolerance
por: Jang, Eun-Hee, et al.
Publicado: (2013)

FoxO1 Gain of Function in the Pancreas Causes Glucose Intolerance, Polycystic Pancreas, and Islet Hypervascularization
por: Kikuchi, Osamu, et al.
Publicado: (2012)

Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography
por: van den Brom, Charissa E, et al.
Publicado: (2009)

Intra-islet glucagon confers β-cell glucose competence for first-phase insulin secretion and favors GLP-1R stimulation by exogenous glucagon
por: Cabrera, Over, et al.
Publicado: (2021)

Transgenerational Glucose Intolerance With Igf2/H19 Epigenetic Alterations in Mouse Islet Induced by Intrauterine Hyperglycemia
por: Ding, Guo-Lian, et al.
Publicado: (2012)

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
por: Sloop, Kyle W., et al.
Publicado: (2010)

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets
por: Yang, Xiaohua, et al.
Publicado: (2021)

Metabolic changes in type 2 diabetes are reflected in peripheral blood cells, revealing aberrant cytotoxicity, a viral signature, and hypoxia inducible factor activity
por: van der Pouw Kraan, Tineke C. T. M., et al.
Publicado: (2015)

Glucose Decouples Intracellular Ca(2+) Activity from Glucagon Secretion in Mouse Pancreatic Islet Alpha-Cells
por: Le Marchand, Sylvain J., et al.
Publicado: (2012)

Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases
por: Lee, Young-Sun, et al.
Publicado: (2018)

Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes
por: Fuselier, Taylor, et al.
Publicado: (2022)

Conditional ablation of HDAC3 in islet beta cells results in glucose intolerance and enhanced susceptibility to STZ-induced diabetes
por: Chen, Wen-Bin, et al.
Publicado: (2016)

Melatonin and Pancreatic Islets: Interrelationships between Melatonin, Insulin and Glucagon
por: Peschke, Elmar, et al.
Publicado: (2013)

In vivo studies of glucagon secretion by human islets transplanted in mice
por: Tellez, Krissie, et al.
Publicado: (2020)

Small molecule glucagon release inhibitors with activity in human islets
por: Kalwat, Michael A., et al.
Publicado: (2023)

Long-term exposure of mouse pancreatic islets to oleate or palmitate results in reduced glucose-induced somatostatin and oversecretion of glucagon
por: Collins, S. C., et al.
Publicado: (2008)

Activin a is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes
por: Chen, Weena JY, et al.
Publicado: (2013)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Label-Free Detection of Insulin and Glucagon within Human Islets of Langerhans Using Raman Spectroscopy
por: Hilderink, Janneke, et al.
Publicado: (2013)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Short‐Term Glucocorticoid Treatment Reduces Circulating Sclerostin Concentrations in Healthy Young Men: A Randomized, Placebo‐Controlled, Double‐Blind Study
por: Jacobsson, Merel, et al.
Publicado: (2020)

Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes
por: Steinbusch, Laura K. M., et al.
Publicado: (2011)

A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro
por: Verma, Mahesh Kumar, et al.
Publicado: (2014)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rtf53q8i2a62058msp1j2vu5v8